Cytek Biosciences ownership filing: Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of 6,638,827 shares of Common Stock, representing 5.2% of the class as of the filing. The holders executed a joint filing agreement dated April 8, 2026.
The filing lists the issuers' principal executive office in Fremont, California, and identifies the securities by CUSIP 23285D109. The reporting persons state voting and dispositive power as shared through affiliated entities.
Positive
None.
Negative
None.
Insights
Large passive stake disclosure by Millennium group; routine Schedule 13G reporting.
The filing documents a 5.2% shared position of 6,638,827 shares, reported via a joint filing agreement among related entities. Schedule 13G treatment typically indicates passive investment intent rather than active control.
Materiality is limited: the position is notable for disclosure thresholds but does not in isolation imply governance changes. Subsequent filings could clarify any change in intent.
Key Figures
Shares beneficially owned:6,638,827 sharesPercent of class:5.2%CUSIP:23285D109+1 more
4 metrics
Shares beneficially owned6,638,827 sharesreported on Schedule 13G / joint filing dated April 8, 2026
Percent of class5.2%percent of Common Stock as stated on cover pages
CUSIP23285D109Common Stock identifier in the filing
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
shared dispositive powerfinancial
"Shared Dispositive Power 6,638,827.00"
joint filing agreementregulatory
"Joint Filing Agreement, dated as of April 8, 2026"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Cytek Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
23285D109
(CUSIP Number)
04/02/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
23285D109
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,638,827.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,638,827.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,638,827.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
23285D109
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,638,827.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,638,827.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,638,827.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
23285D109
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,638,827.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,638,827.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,638,827.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Cytek Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
47215 Lakeview Boulevard, Fremont, California 94538
Item 2.
(a)
Name of person filing:
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP Number(s):
23285D109
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
(b)
Percent of class:
See response to Item 11 on each cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
04/08/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
04/08/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
04/08/2026
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of April 8, 2026, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
What stake does Millennium report in Cytek Biosciences (CTKB)?
Millennium reports shared ownership of 6,638,827 shares, or 5.2% of CTKB. The position is reported on a Schedule 13G with a joint filing agreement dated April 8, 2026, indicating ownership via affiliated entities with shared voting and dispositive power.
Does the Schedule 13G for CTKB indicate active control or takeover intent?
The filing is a Schedule 13G, which typically signals passive intent. The report lists shared voting and dispositive power through affiliated managers; it does not state activist actions or plans to change control in the provided excerpt.
Who are the reporting parties listed on the CTKB Schedule 13G?
The reporting persons are Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. Addresses shown are 399 Park Avenue, New York, NY, and signatures include a joint filing agreement dated April 8, 2026.
What security and identifier are covered in the CTKB filing?
The filing covers Common Stock, par value $0.001 per share, CUSIP 23285D109. The issuer's principal executive office is listed as 47215 Lakeview Boulevard, Fremont, California.
How does the filing describe voting and dispositive power for the CTKB shares?
The report shows 0 sole voting/dispositive power and 6,638,827 shared voting/dispositive power. It explains the shares are held by entities subject to voting control and investment discretion by the reporting managers.
